Showing results (561-570 of 587) with videos related to
Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.Cancer Discovery|June 22, 2026
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancerWilliam J McDaid, Helen Adderley, Paolo D d'Arienzo, et al.Radiology|November 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with MetastasesLama Dawi, Younes Belkouchi, Littisha Lawrance, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus ReportAnne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR TrialSolange Peters, Sarah Danson, Baktiar Hasan, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.Cancer Cell|April 18, 2026
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 studyDavid Planchard, Nathalie Cozic, Maria Fernanda Mosele, et al.Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Pageof 59